SK279869B6 - Farmaceutický lyofilizovaný prípravok na báze ifos - Google Patents

Farmaceutický lyofilizovaný prípravok na báze ifos Download PDF

Info

Publication number
SK279869B6
SK279869B6 SK3176-92A SK317692A SK279869B6 SK 279869 B6 SK279869 B6 SK 279869B6 SK 317692 A SK317692 A SK 317692A SK 279869 B6 SK279869 B6 SK 279869B6
Authority
SK
Slovakia
Prior art keywords
ifosfamide
urea
weight
lyophilized
formulations
Prior art date
Application number
SK3176-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK317692A3 (en
Inventor
Robert L. Alexander
Robert J. Behme
Joseph A. Scott
Dana Brooke
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK317692A3 publication Critical patent/SK317692A3/sk
Publication of SK279869B6 publication Critical patent/SK279869B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK3176-92A 1991-10-23 1992-10-20 Farmaceutický lyofilizovaný prípravok na báze ifos SK279869B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/781,436 US5227373A (en) 1991-10-23 1991-10-23 Lyophilized ifosfamide compositions

Publications (2)

Publication Number Publication Date
SK317692A3 SK317692A3 (en) 1995-11-08
SK279869B6 true SK279869B6 (sk) 1999-04-13

Family

ID=25122737

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3176-92A SK279869B6 (sk) 1991-10-23 1992-10-20 Farmaceutický lyofilizovaný prípravok na báze ifos

Country Status (24)

Country Link
US (1) US5227373A (zh)
EP (1) EP0538858B1 (zh)
JP (1) JP3576180B2 (zh)
KR (1) KR100247161B1 (zh)
CN (1) CN1046202C (zh)
AT (1) ATE175354T1 (zh)
AU (1) AU658011B2 (zh)
CA (1) CA2081061A1 (zh)
CZ (1) CZ282445B6 (zh)
DE (1) DE69228105T2 (zh)
DK (1) DK0538858T3 (zh)
EG (1) EG20114A (zh)
ES (1) ES2125880T3 (zh)
FI (1) FI107701B (zh)
GR (1) GR3029835T3 (zh)
HU (2) HU221428B (zh)
IL (1) IL103496A (zh)
MX (1) MX9206105A (zh)
MY (1) MY109794A (zh)
NZ (1) NZ244816A (zh)
RU (1) RU2106138C1 (zh)
SK (1) SK279869B6 (zh)
TW (1) TW217987B (zh)
ZA (1) ZA928104B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin
ATE348621T1 (de) * 1997-10-13 2007-01-15 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
ATE397440T1 (de) * 2002-02-22 2008-06-15 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
BR0314068A (pt) * 2002-09-05 2005-07-05 Bharat Serums & Vaccines Ltd Processo para a preparação de uma composição estável com baixo nìvel de toxicidade; composição estável que contém oxazafosforina; uso de uma composição estável que contém oxazafosforina; e método de tratamento de uma doença maligna
MXPA05005919A (es) * 2002-12-02 2005-09-21 Bharat Serums & Vaccines Ltd Composiciones de ifosfamida para la administracion parenteral, y un proceso para su preparacion.
US7199111B2 (en) * 2002-12-02 2007-04-03 Bharat Serums & Vaccines Ltd. Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
DK1667655T3 (da) * 2003-10-01 2011-10-24 Baxter Int Ny anvendelse, farmaceutiske præparater og en fremgangsmåde til deres fremstilling
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP2071917B1 (en) * 2006-09-29 2012-11-21 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
WO2008140724A1 (en) * 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
EP3266448B1 (en) 2009-03-27 2022-02-16 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
CN102459568A (zh) * 2009-05-26 2012-05-16 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
SG182317A1 (en) 2010-01-28 2012-08-30 Advanced Bionutrition Corp Dry glassy composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
RS57588B1 (sr) 2010-08-13 2018-11-30 Advanced Bionutrition Corp Supstanca za stabilizaciju bioloških materijala za suvo skladištenje
WO2015101665A1 (en) 2014-01-06 2015-07-09 Auxin Surgery Sa Lyophilized mesna compositions
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
AU2016297986B8 (en) 2015-07-29 2020-06-11 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
ZA851062B (en) * 1984-03-01 1985-11-27 Asta Werke Ag Chem Fab Salts of oxazaphosphorine derivatives and process for their production
ATE66609T1 (de) * 1986-07-11 1991-09-15 Asta Pharma Ag Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
EP0281832B1 (de) * 1987-03-06 1991-05-02 ASTA Pharma Aktiengesellschaft Verfahren zur Herstellung von Ifosfamid mit verbesserten Eigenschaften
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide

Also Published As

Publication number Publication date
HUT69384A (en) 1995-09-28
JP3576180B2 (ja) 2004-10-13
FI924797A (fi) 1993-04-24
NZ244816A (en) 1994-06-27
AU2716692A (en) 1993-04-29
AU658011B2 (en) 1995-03-30
MX9206105A (es) 1993-04-01
JPH05246856A (ja) 1993-09-24
CA2081061A1 (en) 1993-04-24
EP0538858B1 (en) 1999-01-07
DK0538858T3 (da) 1999-08-30
MY109794A (en) 1997-06-30
US5227373A (en) 1993-07-13
CZ317692A3 (en) 1993-09-15
HU211293A9 (en) 1995-11-28
FI107701B (fi) 2001-09-28
KR930007453A (ko) 1993-05-20
TW217987B (zh) 1993-12-21
CN1073358A (zh) 1993-06-23
CZ282445B6 (cs) 1997-07-16
DE69228105T2 (de) 1999-08-26
IL103496A0 (en) 1993-03-15
CN1046202C (zh) 1999-11-10
ZA928104B (en) 1993-07-20
EG20114A (en) 1997-07-31
KR100247161B1 (ko) 2000-04-01
ES2125880T3 (es) 1999-03-16
HU221428B (en) 2002-10-28
ATE175354T1 (de) 1999-01-15
HU9203306D0 (en) 1992-12-28
GR3029835T3 (en) 1999-06-30
RU2106138C1 (ru) 1998-03-10
SK317692A3 (en) 1995-11-08
DE69228105D1 (de) 1999-02-18
EP0538858A1 (en) 1993-04-28
FI924797A0 (fi) 1992-10-22
IL103496A (en) 1996-07-23

Similar Documents

Publication Publication Date Title
SK279869B6 (sk) Farmaceutický lyofilizovaný prípravok na báze ifos
US4537883A (en) Lyophilized cyclophosphamide
US20090093522A1 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
JP4703854B2 (ja) 安定な非晶質アミフォスチン組成物およびその製造法および使用法
EA013324B1 (ru) Фармацевтические композиции бендамустина, предназначенные для лиофилизации
FI89456B (fi) Foerfarande foer framstaellning av ifosfamid-mesna-lyofilisat
CA3040018A1 (en) Pharmaceutical parenteral formulation containing carglumic acid
US5750131A (en) Ifosfamide lyophilizate preparations
US6841545B2 (en) Stable amorphous amifostine compositions and methods for the preparation of same
US9211262B2 (en) Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
US5227374A (en) Lyophilized cyclophosphamide
SK135294A3 (en) Lyophilisate preparation contains 1,1',1''- -phosphinothioylindintrisaziridine and method of its production
WO2002002125A1 (en) Injectable composition
US8716521B2 (en) Formulations of canfosfamide and their preparation
WO1995007083A1 (en) Ifosfamide lyophilisate composition
US20240082253A1 (en) Lyophilized composition of copanlisib salt
US20080096947A1 (en) Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
WO2023214433A1 (en) Stable parenteral compositions of parecoxib
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
WO1994008592A1 (en) Lyophilized cyclophosphamide compositions

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20101020